Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products, has successfully raised an undisclosed amount in its Series B financing round. The round was led by Qiming Venture Partners, a returning investor, and the funds will be allocated to the research and development of novel energy-based device products, global marketing and promotion, and the construction of automatic production lines.
Company Background and Product Portfolio
Founded in 2017, Saints Sages Surgical has made significant strides in the field of minimally invasive surgery. The company’s flagship product, the SA01 SAS series ultrasonic soft tissue cutting hemostasis system, is its first Category III device approved in China in 2021. This device is equipped with RTTE I (real-time tissue effect I), a first-generation real-time tissue adaptive algorithm that enhances surgical precision and safety.
Innovation and Regulatory Approvals
Building on its success, Saints Sages Surgical received approval for its self-described first-in-class portable integrated ultrasound soft tissue cutting hemostasis system, SA10 SASD, in China in September last year. This Category III product features the second-generation real-time tissue adaptive algorithm, RTTE II (real-time tissue effect II), marking a significant advancement in the company’s product lineup.-Fineline Info & Tech
